吉非罗齐与辛伐他汀治疗糖尿病高脂血症及对血液流变学影响的比较

目的 :比较吉非罗齐与辛伐他汀治疗糖尿病高脂血症疗效及对血液流变学的影响。方法 :吉非罗齐组 3 6例 (男性 16例 ,女性 2 0例 ,年龄 61a±s11a) ,给吉非罗齐 3 0 0mg ,bid× 45d ;辛伐他汀组3 2例 (男性 13例 ,女性 19例 ,年龄 63a± 10a) ,给辛伐他汀 2 0mg ,qd× 45d。结果 :2组降胆固醇有效率分别为 5 6% ,72 % (P >0 .0 5 ) ,降三酰甘油有效率分别为 89% ,5 0 % (P <0 .0 5 ) ,升高密度脂蛋白胆固醇有效率分别为 5 3 % ,47% (P >0 .0 5 ) ,用吉非罗齐后凝血因子Ι显著下降 (P <0 .0 1)。 2组不良反应轻微。结论 :吉非罗齐与辛伐他汀调脂作用肯定 ,吉非罗齐降三酰甘油的作用优于辛伐他汀 ,能改善血粘度 ,并且安全。

Gemfeibrozil vs simvastatin in treating diabetic hyperlipidemia and affecting hemorheology

AIM:To compare the effect of gemfeibrozil and simvastatin in treating diabetic hyperlipidemia and affecting hemorheology. METHODS:Thirty six patients(M 16,F 20; age 61 a± s 11 a) received gemfeibrozil 300 mg, po , bid for 45 d and 32 patients (M 13,F 19; age 63 a±10 a) received simvastatin 20 mg po ,qd for 45 d. RESULTS:The total effective rates for reducing total cholesterol (TC) and triglyceride (TG)in gemfeibrozil group and simvastatin group were 56 %,89 % and 72 %,50 % respectively( P >0.05 and P <0.05).The total effective rates for raising high density 1ipoprotein cholesterol (HDL C) in gemfeibrozil group and simvastatin group were 53 %,47 % respectively ( P >0.05).The blood clotting factor Ι. was reduced significantly in gemfeibrozil group treated with gemfeibrozil. No significant adverse reaction was observed in two groups. CONCLUSION:Gemfeibrozil is a good drug in adjusting blood lipid and reducing plasma blood clotting factor Ι. In reducing TG gemfeibrozil is better than simvastatin.